Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.75p +11.48% 17.00p 16.50p 17.50p 17.25p 15.25p 15.25p 328,114 12:41:53
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.0 -3.3 - 16.82

Evgen Pharma Share Discussion Threads

Showing 1326 to 1347 of 1350 messages
Chat Pages: 54  53  52  51  50  49  48  47  46  45  44  43  Older
DateSubjectAuthorDiscuss
18/3/2019
11:11
mirako - not necessarily - the whole FDA accelerated approval pathway was set up to use surrogate endpoints eg biomarkers. I'm not sure how that position will change with Gottlieb moving, but I think accelerated approval is a very attractive option for a company like Evgen and they should be looking at it very closely.
supernumerary
18/3/2019
10:43
The primary endpoint in this trial is a biomarker and the FDA will surely want evidence of clinical benefit.
mirako
18/3/2019
10:39
It's clearly the correct thing to do, and as Nobby says, surprising that it wasn't always the case. I'm also curious about why they seem to be planning to make the current secondary endpoints into the primary endpoints in the next trial. If they get to the next phase it will be because they've succeeded in this one, so why change a winning formula?
supernumerary
18/3/2019
08:51
Encouraging move this morning with about £20k shares bought. Could be an interesting week ahead of the results next week....
nobbygnome
18/3/2019
07:59
Could really take off.
1hopefultrader
18/3/2019
07:57
I guess it makes sense to announce all the SAH results together but I do wonder why they have only realised that now. Good the breast cancer results are out next week. Hopefully good results will mean that sulforaphane will proceed on to another trial!
nobbygnome
18/3/2019
07:30
got to be in it to win it gl 90p
purple11
18/3/2019
07:29
Evgen Pharma plc ("Evgen Pharma" or "the Company") Update on SFX-01 trial read-out dates Final read-out data from Phase II STEM trial expected next week Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the following update on the read-out of its two Phase II trials of SFX-01, the Company's lead development product. The final read-out of the STEM trial in metastatic breast cancer is expected to be announced early next week, in line with the Company's earlier guidance of Q1 2019. In the SAS trial of SFX-01 in subarachnoid haemorrhage, the Company is pleased to confirm that the treatment phase of the trial has now concluded with the last patient on the trial having received the final patient dose. Following advice from clinicians and statisticians, and in the light of commercial considerations, the Company has decided to announce the primary endpoints (safety, tolerability and measures of blood flow in the brain) and secondary endpoints (relating to cognitive function) at the same time, rather than announcing them separately as previously indicated. This approach fully protects the blinded integrity of the secondary endpoint data which continues to be collected post-dosing for six months from the initial haemorrhage. The SAS trial will therefore remain fully blinded until all of the secondary endpoint data has been collected. The final read-out continues to be expected in late summer 2019. Steve Franklin, CEO of Evgen Pharma, commented: "This is a hugely exciting time for Evgen as we build up to the read-out early next week of our Phase II clinical trial of SFX-01 in metastatic breast cancer. These results are expected to be followed in the late summer this year by the final read-out of our SAS Phase II trial of SFX-01 in subarachnoid haemorrhage. "Following discussions with our clinicians and statistical advisers, we have decided to unblind the SAS trial's primary and secondary endpoint data at the same time. By doing this, we will fully maintain the blinded integrity of the secondary endpoint data, which in this trial are particularly important as they will form the basis of the primary endpoints in subsequent studies. This approach will maximise the commercial value of the dataset from the SAS trial."
purple11
13/3/2019
16:52
jonnybgood4 filtered. His message has been posted on all the biotech threads. And Firefox warned that the 4d pharma website (in English and Chinese) was insecure. DYOR etc.
stopstopgo
12/3/2019
12:34
This wait seems even more frustrating as we already know the end points have been met.. or is it just my lack of patience showing through here?
l0ngterm
06/3/2019
19:25
The ceo has said repeatedly let the science do the talking, not the PR team. So investors that look for news will get bored, chase something else etc. Others were expecting a spike or rise into the results. So not really surprised at where we are from a share price perspective.
l0ngterm
06/3/2019
16:33
Only small amounts though - AIM is full of penny profit merchants
dave444
06/3/2019
15:35
so close to gamechanging results and always constant selling.. so irritating.
purple11
05/3/2019
18:00
I must learn how to spell. In my previous post I should of course have said sulforadex. I have now registered the word "sulphoradex", and will seek compensation from anybody on the BB using it.
stopstopgo
05/3/2019
08:21
Oncology result in next 26 days!
dave444
05/3/2019
07:19
Yes we could get a company coming in or at the very least grant funding through the various NHSE routes
dave444
05/3/2019
07:15
Agree, seems to perform better than market leader. Will it lead to company being taken over I wonder?
ayl30
05/3/2019
07:13
That is positive
dave444
27/2/2019
17:14
If the results in the breast cancer trial are positive the next proposed step is a trial involving combination with Exemestane. I came across the following article; Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention hTTps://www.pnas.org/content/110/47/19065 As dave444 says we don't have long to wait. If they achieve 20% responders for the six months hopefully the market will view it as a success. However, the response at the interim readout was lukewarm at best.
pdt
27/2/2019
13:46
We will have the result inside the next 32 days according to the RNS!
dave444
25/2/2019
08:07
Timbo003, I'm a small investor, would like to have bought more but I have lots of plans while I'm still well 😀😀
blakeysangel
25/2/2019
01:07
>>>Blakeysangel, good to hear you are still going strong and keeping so positive. Can you remind me, did you ever buy a few shares in Evgen?
timbo003
Chat Pages: 54  53  52  51  50  49  48  47  46  45  44  43  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190318 14:00:38